Companies in #Infectious Disease

Anixa Biosciences is a clinical-stage biotechnology company developing vaccines and therapeutics for cancer and infectious disease. Lead programs include a breast cancer vaccine licensed from Cleveland Clinic and an ovarian cancer vaccine in collaboration with Moffitt Cancer Center.

Global mid-sized Contract Research Organization (CRO) operating in 23 countries, providing patient-centric clinical trial solutions for biopharma innovators across oncology, rare disease, and cell & gene therapy programs.

Innoviva Inc. (NASDAQ: INVA) is a specialty pharmaceutical company with a diversified portfolio of marketed therapeutics and a growing focus on long-acting drug delivery. The company is reviving the Lyndra Therapeutics long-acting oral drug platform, originally developed at Bob Langer's MIT lab, with Langer and Janet Woodcock as senior advisors.

RQ Bio is a UK-based biotechnology company developing a portfolio of virus-targeting monoclonal antibodies. The company emerged from research at the Rosalind Franklin Institute and raised a $115M Series A in 2026 to advance its preclinical pipeline of broadly neutralizing antibodies against viral pathogens.

Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. Its platform collects and analyzes clinical and molecular data to enable physicians and researchers to make data-driven decisions in oncology, cardiology, and other disease areas.

Services: Global healthcare company formed in November 2020 via Mylan-Upjohn combination; portfolio spans branded (Xulane, Yupelri, Effient, Dilantin, Cordarone, Sarafem, Dymista), generics (~1,400 molecules across all therapeutic areas), biosimilars, complex generics; therapeutic focus: cardiology, infectious disease, immunology, oncology, ophthalmology, dermatology, respiratory, CNS; significant emerging markets presence through legacy Mylan platforms; now executing Phase II of strategic plan with portfolio optimization